Premium
Punto de vista: Alcanzar los objetivos de la iniciativa STOP TB Partnership : perspectivas sobre el desarrollo de nuevos diagnósticos, medicamentos y vacunas para la tuberculosis
Author(s) -
Mwaba Peter,
McNerney Ruth,
Grobusch Martin Peter,
O’Grady Justin,
Bates Matthew,
Kapata Nathan,
Maeurer Markus,
Zumla Alimuddin
Publication year - 2011
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2011.02777.x
Subject(s) - general partnership , medicine , tuberculosis , intensive care medicine , global health , investment (military) , economic growth , environmental health , public health , political science , politics , nursing , pathology , law , economics
Summary Global eradication of tuberculosis (TB) depends on identification and treatment of all active TB cases and of the two billion people who are estimated to be latently infected with Mycobacterium tuberculosis . The past decade has seen a renaissance of scientific activities and funder investment into development of new TB drugs, diagnostics, biomarkers and vaccines. This viewpoint critically summarises the promising portfolio of more accurate TB diagnostics, new TB drugs and vaccines that have been endorsed by the STOP TB Partnership. Increasing numbers of Phase 2 and 3 drug, vaccine and diagnostic clinical trials in high‐TB endemic areas reflect substantial progress towards attaining Global STOP‐TB Partnership targets. Achievement of STOP‐TB Partnership goals will crucially depend on political will and serious investment by funders and developing country governments into improving delivery of better health services and living conditions for their people. Long‐term sustainability of any newer tools implemented at point of care is essential.